
-
Foghorn Therapeutics NASDAQ:FHTX Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The Company's proprietary Gene Traffic Control® platform gives it an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system.
Location: | Website: foghorntx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-15.31M
Cash
243.7M
Avg Qtr Burn
-25.1M
Short % of Float
3.78%
Insider Ownership
18.94%
Institutional Own.
72.55%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FHD-909 Details Cancer, Non-small cell lung carcinoma | Phase 1 Update | |
FHD-286 Details Metastatic Uveal Melanoma | Failed Discontinued | |
FHD-609 Details Synovialsarcoma, Sarcoma | Failed Discontinued | |
FHD-286 + decitabine or low-dose cytarabine (LDAC) Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Failed Discontinued |